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series
EMCDDA initial reports are drawn up on one or several similar new 
psychoactive substances that may pose health or social risks at European 
Union level. 
Initial reports provide scientific evidence to the Commission in order to allow 
it to make an informed decision regarding whether or not there is a need to 
request a risk assessment on a new psychoactive substance.
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Statement regarding the United Kingdom 
The reference period for this report includes 2019 and 2020 (up to the moment of writing). 
The United Kingdom left the European Union as of 1 February 2020. However, during the 
transitional period, the UK continues to participate in the European Union Early Warning 
System on new psychoactive substances. Unless stated otherwise, for the purpose of this 
report, the term ‘Member States’ shall include the United Kingdom.  
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1. Introduction  
N,N-Diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(isotonitazene) is a synthetic opioid analgesic. It is a member of the benzimidazole family of 
opioids which includes etonitazene, a potent internationally controlled opioid analgesic (1). 
Although the size of the market is unknown, isotonitazene is sold online as a legal 
replacement to controlled opioids; it also appears to have been sold on the illicit opioid 
market at street-level in a small number of countries. Similar to other opioid analgesics, the 
most serious acute health risk from using isotonitazene is likely to be respiratory depression, 
which in overdose could lead to apnoea, respiratory arrest, and death.  
In Europe, isotonitazene is monitored by the EMCDDA as a new psychoactive substance (2) 
through the European Union Early Warning System (EWS) in accordance with Article 5a of 
Regulation (EC) No 1920/2006 (as amended) (3,4). 
Isotonitazene was formally notified as a new psychoactive substance (5,6) by the EMCDDA 
on behalf of Belgium on 26 August 2019. The notification was based on the identification of 
the substance in a collected sample of powder that was a test purchase from a private online 
vendor that was received on 1 July 2019. However, based on information subsequently 
reported to the EMCDDA concerning a seizure made by police in Estonia, isotonitazene has 
been available on the European drug market since at least April 2019. 
Since the formal notification, information on isotonitazene has been exchanged between the 
EMCDDA and the European Union EWS Network (EMCDDA, Europol, Reitox national focal 
points, and the Commission); the EMA have been kept duly informed. 
On 7 February 2020, the EMCDDA issued a public health advisory to the Network 
highlighting an increase in the number of identifications of isotonitazene in Europe and the 
potential risks posed by this. The advisory also informed the EWS Network that based on 
potential public health risks, the EMCDDA had added isotonitazene to the list of new 
psychoactive substances under intensive monitoring (7) and requested that the Network 
expedite reporting of any event involving isotonitazene to the EMCDDA until further notice. 
                                                       
(1) Etonitazene is controlled under Schedule I of the 1961 United Nations Single Convention on Narcotic Drugs. 
https://www.incb.org/documents/Narcotic-Drugs/Yellow_List/58th_Edition/Yellow_List_-ENG.pdf 
(2) As defined in point 4 of Article 1 of Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum 
provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (OJ L 335, 11.11.2004, 
p. 8). 
(3) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European 
Monitoring Centre for Drugs and Drug Addiction (recast) (O J L 376, 27.12.2006, p.1-13). 
(4) Regulation (EU) 2017/2101 of the European Parliament and of the Council of 15 November 2017 amending Regulation (EC) 
No 1920/2006 as regards information exchange on, and an early warning system and risk assessment procedure for, new 
psychoactive substances (O J L 305, 21.11.2017, p.1-7). 
(5) EMCDDA (2020), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances, p. 15–6. http://www.emcdda.europa.eu/publications/guidelines/operating-guidelines-for-the-european-union-early-
warning-system-on-new-psychoactive-substances_en 
(6) EMCDDA (2020), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances, Guidance note 2. Formal notification of a new psychoactive substance. 
https://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Note%202-
%20Formal%20notification%20of%20a%20new%20psychoactive%20substance.pdf 
(7) EMCDDA (2020), EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances, Guidance note 6. Intensive monitoring. 
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Article 5b of Regulation (EC) No 1920/2006 (as amended) requires that ‘Where the Centre, 
the Commission or a majority of the Member States considers that information shared on a 
new psychoactive substance collected pursuant to Article 5a in one or more Member States 
gives rise to concerns that the new psychoactive substance may pose health or social risks 
at Union level, the Centre shall draw up an initial report on the new psychoactive substance’.  
The initial report is submitted to the Commission and the Member States. The purpose of the 
initial report is to provide scientific evidence to the Commission to allow it to make an 
informed decision regarding whether or not there is a need to request a risk assessment on 
a new psychoactive substance as set out in Article 5c of Regulation (EC) No 1920/2006 (as 
amended). 
Based on the information reported by the Network, on 20 February 2020, the EMCDDA 
assessed the existing information (8,9) on isotonitazene, based on the following criteria:  
§ reports of health problems; 
§ reports of social problems; 
§ reports of seized material; 
§ pharmacological and toxicological properties and analogy with better-studied 
substances; and, 
§ potential for further spread.  
The EMCDDA concluded that the assessment gave rise to concerns that isotonitazene may 
pose health or social risks at Union level, and, consequently, determined that an initial report 
should be produced. 
2. Information collection process 
In accordance with the requirements of Article 5b of the Regulation, on 28 February 2020, 
the EMCDDA launched a procedure for the collection of additional information on 
isotonitazene in order to support the production of the initial report.  
The EMCDDA collected information through: 
§ a structured reporting form to the Reitox national focal points in the Member 
States, Turkey, and Norway (Article 5b(4)); 
§ routine monitoring of open source information;  
§ a search of open source information conducted specifically for the production of the 
initial report which included: scientific and medical literature, official reports, grey 
                                                       
http://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Note%206-
%20Intensive%20monitoring.pdf 
(8) European Monitoring Centre for Drugs and Drug Addiction (2019), EMCDDA operating guidelines for the European Union 
Early Warning System on new psychoactive substances, Publications Office of the European Union, Luxembourg. 
http://www.emcdda.europa.eu/publications/guidelines/operating-guidelines-for-the-european-union-early-warning-system-on-
new-psychoactive-substances_en 
(9) This included information reported to the EMCDDA through the Early Warning System, including case reports and 
aggregated datasets. 
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literature, internet drug discussion forums and related websites (hereafter, ‘user 
websites’), and online vendors. 
In addition, the EMCDDA also submitted requests to: 
§ The World Health Organization (WHO) in order to determine if isotonitazene is 
under assessment or has been under assessment within the system established 
by the 1961 Single Convention on Narcotic Drugs, as amended by the 1972 
Protocol, and the 1971 Convention on Psychotropic Substances (‘United Nations 
system’). 
§ The European Medicines Agency (EMA) in order to determine if isotonitazene is 
used as an active substance in a medicinal product for human or veterinary use at 
Union or national level (Article 5b(5)). Specifically, the EMA was asked if 
isotonitazene is an active substance in: 
a. a medicinal product for human use or in a veterinary medicinal product that 
has obtained a marketing authorisation in accordance with Directive 2001/83/ 
EC of the European Parliament and of the Council (10), Directive 2001/82/EC 
of the European Parliament and of the Council (11) or Regulation (EC) No 
726/2004 of the European Parliament and of the Council (12);  
b. a medicinal product for human use or in a veterinary medicinal product that is 
the subject of an application for a marketing authorisation;  
c. a medicinal product for human use or in a veterinary medicinal product whose 
marketing authorisation has been suspended by the competent authority;  
d. an unauthorised medicinal product for human use in accordance with Article 5 
of Directive 2001/83/EC or in a veterinary medicinal product prepared 
extemporaneously by a person authorised to do so under national law in 
accordance with point (c) of Article 10(1) of Directive 2001/82/EC;  
e. an investigational medicinal product as defined in point (d) of Article 2 of 
Directive 2001/20/EC of the European Parliament and of the Council (13). 
§ Europol in order to provide information on the involvement of criminal groups in the 
manufacture, distribution and distribution methods, and trafficking of isotonitazene, 
and in any use of isotonitazene (Article 5b(6)).  
§ The European Chemicals Agency (ECHA), the European Centre for Disease 
Prevention and Control (ECDC) and the European Food Safety Authority (EFSA) in 
                                                       
(10) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating 
to medicinal products for human use (OJ L 311, 28.11.2001, p. 67). 
(11) Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating 
to veterinary medicinal products (OJ L 311, 28.11.2001, p. 1). 
(12) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community 
procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a 
European Medicines Agency (OJ L 136, 30.4.2004, p. 1). 
(13) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the 
conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p. 34). 
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order to provide the information and data at their disposal on isotonitazene (Article 
5b(7)). 
The information collection process was concluded on 27 March 2020. The EMCDDA 
received responses from all 28 Member States, Turkey, and Norway. In addition, the 
EMCDDA received responses from WHO, EMA, Europol, ECHA, ECDC, and EFSA. 
3. Information required by Article 5b(2) of the Regulation 
The order and titles of subsections 3.1 to 3.9, below, are as they appear in Article 5b(2) of 
Regulation (EC) No 1920/2006 (as amended); sections 3.1 to 3.4 are cross-referenced with 
the headings of Article 5b(2a) to Article 5b(2d) of the Regulation. 
3.1 Nature, number and scale of incidents showing health and social problems 
in which the new psychoactive substance may potentially be involved, and the 
patterns of use of the new psychoactive substance (Article 5b(2a)) 
As isotonitazene has only been on the drug market for a short period of time, it may not be 
part of drug screening in many forensic and toxicology laboratories. Therefore, the presence 
of isotonitazene on the European drug market may be undetected in some areas, including 
in law enforcement seizures as well as in biological samples related to serious adverse 
events. It is also important to note, that, due to differences in reporting practices across 
Europe, identifications of isotonitazene may be unreported to the Reitox national focal points 
and as a consequence to the EMCDDA.  
3.1.1 Information from seizures, collected samples and biological samples 
As of 28 March 2020, isotonitazene has been identified in six Member States: Belgium, 
Estonia, Germany, Latvia, Sweden, and the United Kingdom. These relate to police seizures 
reported by Estonia, Germany, and Latvia; a customs seizure reported by Sweden; a 
collected sample reported by Belgium; and biological samples from a death case reported by 
the United Kingdom. 
Information from seizures 
Law enforcement seizures of isotonitazene have been reported in four Member States: 
Estonia, Latvia, Germany, and Sweden. In total, 24 seizures were reported. In 22 cases 
isotonitazene was seized in powder form (total of 109.6 g of powder) and in two cases in 
liquid form (4.5 g).  
Police seizures  
A total of 23 seizures of isotonitazene made by police were reported by Estonia (n=17), 
Latvia (n=4), and Germany (n=2). Where known, the seizures took place between April 2019 
and January 2020.  
In 21 cases, isotonitazene was seized in powder form totalling 60.8 g (range from 0.013 to 
19.8 g); the colour of the powder was described as brown in some of the cases reported by 
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Estonia. Information on the amount of isotonitazene present in the seizures was not 
reported. Estonia reported that the only other substances detected in the powders were 
‘common sugars’ (not further specified); Latvia reported that one seizure also contained 
fentanyl. Estonia reported that some of the seizures related to small-scale 
distribution/supply. In one case reported by Latvia, powders of isotonitazene were found in 
19 individual foil packages also suggesting small-scale distribution/supply.  
In two cases reported by Germany, the seized products were liquids (product name: 
"ISOTONITAZEN EXTRA STRONG") and also contained trace amounts of the synthetic 
cannabinoid 5F-MDMB-P7AICA. 
Customs seizures  
Sweden reported one seizure of isotonitazene that was made by customs. The seizure took 
place in September 2019. A total of 48.8 g of powder was seized; the colour was described 
as yellow. Information on the amount of isotonitazene present in the seizure was not 
reported. The seized package originated from China and the destination was Sweden.  
Information from collected samples  
Belgium reported a collected sample of isotonitazene. It was a test purchase made by the 
national focal point via a private Telegram-group linked to a private website. The sample 
was incorrectly advertised as ‘etonitazene’. The cost was $400 per 1 g. It was received as a 
white powder in a plastic zip-lock bag which was then packaged inside a foil bag, with the 
label ‘iso’. Based on the analyses conducted, it was reported that the isotonitazene was 
supplied as its hydrochloride salt and that it was of ‘high purity’ (Blanckaert et al., 2019).  
Information from biological samples 
The United Kingdom reported biological samples (blood and urine) from a death in which 
isotonitazene was identified (Section 3.1.2). 
3.1.2 Health problems 
Germany reported a death involving isotonitazene; no further details are currently available.  
The United Kingdom reported a death with confirmed exposure to isotonitazene; 
butyrylfentanyl, despropionyl fentanyl (4-ANPP), and despropionyl fluorofentanyl were also 
identified. All ‘were at very low (estimated sub ng/ml) levels)’. The death occurred in 2019; 
no further details are currently available.  
As isotonitazene is an opioid analgesic, the health risks may have some similarities with 
those associated with controlled opioids such as heroin or the fentanils. 
ECDC reported that currently they do not have any information on isotonitazene at their 
disposal, in particular any data on infectious diseases among isotonitazene users. 
3.1.3 Social problems 
 
There is no specific information on the social risks that may be associated with the use of 
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isotonitazene. As isotonitazene is an opioid analgesic, the social problems may have some 
similarities with those associated with controlled opioids such as heroin or the fentanils. 
3.1.4 Patterns of use 
There is limited information on the patterns of use of isotonitazene. As isotonitazene is an 
opioid analgesic, it could be expected that suppliers as well as users who are looking for 
substitutes for controlled opioids, such as heroin, fentanils, and/or prescription opioids, may 
be interested in isotonitazene.  
User groups may include high-risk drug users, including individuals who inject opioids. 
Similar to other new psychoactive substances, it also appears that there is interest in 
isotonitazene by some psychonauts.  
Anecdotal reports from user websites note a range of routes of administration and doses, 
including use by intravenous injection and nasal sprays (14,15). 
Isotonitazene may be deliberately sought after by some users; others, such as those that 
purchase it at street-level, may be unaware that they are using the substance which 
presents an inherent risk to the individuals. 
3.2 Chemical and physical description of the new psychoactive substance and 
the methods and precursors used for its manufacture or extraction (Article 
5b2(b)) 
3.2.1 Chemical description and names 
Isotonitazene belongs to the benzimidazole group of synthetic opioids. In particular, it is a 6-
nitro-2-benzylbenzimidazole. This group also includes etonitazene, which is internationally 
controlled, as well as metonitazene, and protonitazene (16). 
Isotonitazene differs from these substances in the substitution at the para-position of the 
benzyl moiety, which is an iso-propoxy group in isotonitazene, an ethoxy group in 
etonitazene, a methoxy group in metonitazene, and a propoxy group in protonitazene. The 
molecular structure, molecular formula and molecular mass of isotonitazene are provided in 
the figure. 
 
 
 
 
                                                       
(14) https://www.google.com/search?q=site%3A.bluelight.org+isotonitazene&ie=utf-8&oe=utf-8 
(15) https://www.google.com/search?q=site%3A.reddit.com+isotonitazene&ie=utf-8&oe=utf-8 
(16) As of March 2020, neither the identification of metonitazene nor protonitazene have been reported to the EMCDDA via the 
Early Warning System. 
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FIGURE 
Molecular structure, molecular formula, and molecular mass of isotonitazene. 
Information on etonitazene, metonitazene, and protonitazene is provided for 
comparison. 
 
    
 isotonitazene etonitazene (17) metonitazene (18) protonitazene (19) 
Molecular 
formula 
C23H30N4O3 C22H28N4O3 C21H26N4O3 C23H30N4O3 
Molecular 
mass 
410.52 396.48 382.46 410.52 
 
Common name: 
Isotonitazene 
Systematic (IUPAC) name: 
N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-
ethanamine 
Other chemical names: 
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-
amine 
N,N-diethyl-2-[2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl]ethanamine 
N,N-diethyl-2-[2-[(4-isopropoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamine 
N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-
ethanamine 
N,N-diethyl-2-[5-nitro-[2-[(4-propan-2-yloxyphenyl)methyl]benzimidazol-1-yl]-
ethanamine 
1-[2-(diethylamino)ethyl]-2-(p-isopropoxybenzyl)-5-nitrobenzimidazole 
                                                       
(17) N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(18) N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(19) N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
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Street names: 
 ‘iso’ 
Chemical Abstracts Service (CAS) registry numbers: 
 14188-81-9 free base 
119276-00-5 hydrochloride salt 
IUPAC International Chemical Identifier Key (InCHI Key): 
OIOQREYBGDAYGT-UHFFFAOYSA-N 
Simplified Molecular-Input Line-Entry System (SMILES): 
CCN(CC)CCN1C(CC2=CC=C(OC(C)C)C=C2)=NC3=CC([N+]([O-])=O)=CC=C31 
3.2.2 Physical description 
Both the free base and salts of isotonitazene are solids. 
The measured melting point for isotonitazene hydrochloride salt is 172–173 °C (Hoffmann et 
al., 1960; Hunger et al., 1960) (20). 
Isotonitazene is lipophilic (21).  
Isotonitazene, as both the freebase and the hydrochloride salt, is soluble in methanol (NPS 
Discovery, 2019; Blanckaert et al., 2019) and in dimethyl sulfoxide (DMSO) (Blanckaert et 
al., 2019). 
To date, seizures and collected samples containing isotonitazene reported to the EMCDDA 
have been in brown, yellow and white powders. In addition, isotonitazene has also been 
identified in liquid form. Identifications of isotonitazene reported to the EMCDDA include both 
the hydrochloride salt and the free base of the substance. 
3.2.3 Methods and chemical precursors used for the manufacture or extraction 
No information was reported by the Member States, Norway, or Turkey about the chemical 
precursors or manufacturing methods used to make the isotonitazene which has been 
identified within Europe. 
The synthesis of isotonitazene is reported in Hoffmann et al., (1960). It involves the 
condensation of the ortho-phenylenediamine derivative, obtained from 1-chloro-2,4-
dinitrobenzene, in two steps, with phenylacetic acid, benzylcyanide or the corresponding 
imidate. 
                                                       
(20) Belgium reported a collected sample of isotonitazene, purchased through a private Telegram-group. Analysis confirmed the 
hydrochloride salt of isotonitazene. Melting point analysis was conducted and the obtained result of 174 °C is in accordance 
with reported literature values. 
(21) The calculated octanol/water distribution coefficient for isotonitazene is logP = 4.85, using Molinspiration property engine 
v2018.10 (https://www.molinspiration.com/cgi-bin/properties). 
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Although there is no information on the actual manufacturing methods used to make the 
isotonitazene which has been identified in Europe, one possible synthetic route is an 
improved method described for the synthesis of etonitazene by Carroll et al., (1975). The 
authors describe the method as simple, producing high yields, which can be adapted to both 
large scale preparations and for the preparations of other benzimidazole opioids (Carroll et 
al., 1975). Additionally, alkylation by isopropyl bromide of a phenolic species 
(‘desethyletonitazene’), which was reported to be a versatile precursor for other homologues 
(Hoffmann et al., 1959; Hoffmann et al., 1960), may also be used to produce isotonitazene.  
Analytically confirmed detections of the related substance etonitazene on the illicit drug 
market in Moscow, Russia, were reported in 1998 and 1999 (Sorokin et al., 1999a; Sorokin 
et al., 1999b). Information from one of these cases noted that the substance had been 
synthesised in Russia, using a modification of a method published by Hunger et al. (1960). 
These reports also noted the identification of etonitazene on the illicit drug market in 
Germany in 1987, which also apparently used the synthetic route described by Hunger et al., 
(1960). 
Recently, a ‘one-pot’, three component synthesis producing benzimidazole opioids at high 
yield has also been reported (Kim et al., 2011). 
3.2.4 Detection and analysis 
Methods documented in the literature for the identification of isotonitazene in physical 
samples include: gas chromatography–mass spectrometry (GC-MS) (NPS Discovery, 2019; 
Blanckaert et al., 2019; Cayman Chemical, 2020); Fourier transform infrared spectroscopy 
(FTIR), 1H and 13C nuclear magnetic resonance spectroscopy (NMR), Raman spectroscopy 
and ultraviolet spectroscopy (Blanckaert et al., 2019); and high-performance liquid 
chromatography (HPLC) (Blanckaert et al., 2019; Krotulski et al., 2020).  
Methods have also been documented in the literature for the identification of isotonitazene in 
biological samples, which include HPLC and liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) (Krotulski et al., 2020). 
In the analysis by Blanckaert et al., isotonitazene was the only substance present in the 
sample and no impurities were identified (Blanckaert et al., 2019). The authors concluded 
that the sample was of high purity (Blanckaert et al., 2019). 
In the analysis of biological samples by Krotulski et al., the need for increased analytical 
sensitivity when testing for isotonitazene was highlighted following quantitative results which 
were in the low sub-nanogram per millilitre range (Krotulski et al., 2020). 
It is important to note that, since isotonitazene and protonitazene have the same molecular 
mass, their GC-MS analysis will result in very similar mass spectrometry fragmentation 
patterns. The ability to distinguish between isomers requires the use of analytical reference 
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standards, access to reference spectra for both substances, or additional analytical methods 
(22).  
Isotonitazene is available as analytical reference material (23). 
3.3 Pharmacological and toxicological description of the new psychoactive 
substance (Article 5b2(c)) 
Isotonitazene is a synthetic opioid analgesic. It is a member of the benzimidazole family of 
opioids which includes etonitazene, a potent internationally controlled opioid analgesic. 
The available information suggests that isotonitazene may be a potent opioid in humans 
(Hunger et al, 1960; Blanckaert et al., 2019). As such, the effects of isotonitazene are likely 
to share similarities with etonitazene, as well as fentanyl and other opioid analgesics.  
The acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, 
bradycardia, hypothermia, and respiratory depression. They also have an abuse liability and 
dependence potential (Herz, 1993; Kieffer, 1999; Pasternak and Pan, 2013; Pattinson, 2008; 
Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute health risk from using 
isotonitazene is likely to be respiratory depression, which in overdose could lead to apnoea, 
respiratory arrest, and death (EMCDDA, 2017; Pattinson, 2008; White and Irvine, 1999). 
This risk may be greater due to the fact that isotonitazene is the first of the benzimidazole 
opioids to be identified on the drug market in recent years, and users have no experience 
with this family of opioids, including a lack of information on what doses to use and what 
effects the substance can have. The timely administration of the antidote naloxone has been 
shown to be effective in reversing respiratory depression caused by potent opioid analgesics 
(Kim and Nelson, 2015; Boyer, 2012). 
Similarly to other opioid analgesics, the use of isotonitazene with other central nervous 
system (CNS) depressants, including other opioids, sedatives/hypnotics, alcohol, pregabalin, 
gabapentin, tranquillisers, and sedating anti-histamines, is likely to produce additive 
depressant effects which can increase the risk of life-threatening respiratory depression and 
arrest.  
While there is limited information for isotonitazene, the chronic health risks might share 
some similarities to those seen with established opioids, such as heroin and other fentanils. 
This may include dependence. 
ECHA reported to the EMCDDA that they do not currently have any information on 
isotonitazene at their disposal, in particular any data on its toxicological properties. EFSA 
reported to the EMCDDA that they do not currently have any information on isotonitazene at 
their disposal with regards to its acute or chronic toxicity.  
                                                       
(22) Reference standard material for protonitazene is available: https://www.caymanchem.com/product/29381 
(23) https://www.caymanchem.com/product/27255  
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3.4 Involvement of criminal groups in the manufacture or distribution of the 
new psychoactive substance (Article 5b2(d)) 
Europol received replies from 13 Member States: Bulgaria, Croatia, Denmark, Finland, 
Greece, Hungary, Ireland, Lithuania, Luxembourg, Poland, Slovakia, Sweden, and the 
United Kingdom. 
Replies were also received from Norway and the United States Drug Enforcement 
Administration (DEA) (24). 
No information was received on the involvement of criminal groups in the manufacture or 
distribution of isotonitazene. In addition, no information was received in relation to the 
production, distribution (seizures), or trafficking of isotonitazene.  
The United Kingdom reported that isotonitazene can be purchased on the internet. They 
also reported that there is no information available on the involvement of organised crime in 
the manufacture or distribution of isotonitazene in the United Kingdom. 
Europol reported two cases linked to the structurally related substances etonitazene and 
metonitazene. One case involves several ongoing investigations in Czechia regarding the 
purchase of drugs on the darknet. The second case, from 2018 and still under investigation, 
involves seizures of postal parcels in Finland mailed predominately from Poland and which 
mostly related to 2-furanylfentanyl. As part of this investigation, Finland noted that the 
substance metonitazene appeared to be available online in 2018. 
3.5 Information on the human and veterinary medical use of the new 
psychoactive substance, including as an active substance in a medicinal 
product for human use or in a veterinary medicinal product 
Based on the reported information from the EMA (25), it appears that isotonitazene is not an 
active substance in: 
a. a medicinal product for human use or in a veterinary medicinal product that has 
obtained a marketing authorisation in accordance with Directive 2001/83/ EC of the 
European Parliament and of the Council, Directive 2001/82/EC of the European 
Parliament and of the Council or Regulation (EC) No 726/2004 of the European 
Parliament and of the Council;  
b. a medicinal product for human use or in a veterinary medicinal product that is the 
subject of an application for a marketing authorisation;  
                                                       
(24) The formal identification of isotonitazene by the U.S. DEA has not yet been reported. Isotonitazene is not a controlled 
substance or listed chemical under the U.S. Controlled Substances Act. If intended for human consumption, it may be treated 
as a controlled substance analogue, as defined in 21 U.S.C. 802(32)(A), as of October 27, 1986. Reporting indicates that the 
Canadian Border Services Agency (CBSA) has issued alerts on isotonitazene from seizures. Samples of isotonitazene have 
been reported by the US Customs and Borders Protection (CBP). 
(25) 27 Member States, as well as Norway and Iceland provided a response to the EMA’s request regarding human and/or 
veterinary medicinal products. The EMA also provided information as relevant to the centralised procedure for authorising 
human and veterinary medicinal products. 
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c. a medicinal product for human use or in a veterinary medicinal product whose 
marketing authorisation has been suspended by the competent authority. 
In addition, it appears that isotonitazene is not an active substance in the following, although 
the information, especially in relation to use in extemporaneously prepared products, is 
unknown in some cases: 
d. an unauthorised medicinal product for human use in accordance with Article 5 of 
Directive 2001/83/	EC or in a veterinary medicinal product prepared 
extemporaneously by a person authorised to do so under national law in 
accordance with point (c) of Article 10(1) of Directive 2001/82/EC;  
e. an investigational medicinal product as defined in point (d) of Article 2 of Directive 
2001/20/EC of the European Parliament and of the Council. 
3.6 Information on the commercial and industrial use of the new psychoactive 
substance, the extent of such use, as well as its use for scientific research and 
development purposes 
Isotonitazene is used as an analytical reference material in clinical and forensic case work 
as well as scientific research. There is currently no information that suggests isotonitazene is 
used for other legitimate purposes.  
ECHA and EFSA reported that isotonitazene did not retrieve any results in their databases.  
3.7 Information on whether the new psychoactive substance is subject to any 
restrictive measures in the Member States 
Twenty-two Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, 
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, the 
Netherlands, Portugal, Romania, Slovakia, Slovenia, and Spain) reported that isotonitazene 
is not subject to restrictive measures at national level. Turkey also reported that 
isotonitazene is not subject to restrictive measures at national level. 
Drug control legislation 
Four Member States (Estonia, Latvia, Poland, and Sweden) reported that isotonitazene is 
controlled under drug control legislation. 
§ Estonia reported that isotonitazene is controlled under the Act on Narcotic Drugs 
and Psychotropic Substances and Precursors thereof, Annex 1. Narcotic Drugs 
and Psychotropic Substances list since 17 January 2020. 
§ Latvia reported that isotonitazene is controlled under drug control legislation as a 
structural analogue of etonitazene.  
§ Poland reported that isotonitazene is controlled according to the general definition 
of the ‘substitute drug’. 
§ Sweden reported that isotonitazene is regulated as a narcotic since 11 February 
2020. 
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New psychoactive substance legislation 
The United Kingdom reported that isotonitazene is controlled under the Psychoactive 
Substances Act 2016. 
Medicines legislation 
Lithuania and Norway reported that isotonitazene is controlled under medicines legislation. 
§ Lithuania reported that isotonitazene is controlled under medicines legislation since 
11 December 2019.  
§ Norway reported that isotonitazene is controlled under the Norwegian Medicines 
Act. 
3.8 Information on whether the new psychoactive substance is currently or has 
been under assessment within the system established by the 1961 Single 
Convention on Narcotic Drugs, as amended by the 1972 Protocol, and the 1971 
Convention on Psychotropic Substances 
The World Health Organization is the specialised United Nations agency designated for the 
evaluation of the medical, scientific, and public health aspects of psychoactive substances 
under the Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic 
Substances, 1971. 
On 22 March 2020, the World Health Organization informed the EMCDDA that isotonitazene 
is not currently under assessment nor has it been under assessment by the United Nations 
system.  
3.9 Other relevant information 
Information from other countries 
 
Isotonitazene has been identified in 3 deaths in Canada. The deaths occurred in Alberta in 
March, September, and October 2019 (Toxicovigilance Canada, 2019). In addition, 
isotonitazene has been identified in falsified opioid analgesic medicines sold as Dilaudid 
tablets (hydromorphone hydrochloride) that were seized by police during February 2020 
(Halifax Police, 2020). 
Isotonitazene has been identified in at least 18 deaths in the United States. The deaths 
occurred between August 2019 and January 2020 and were from the Midwestern United 
States. Based on information from the death investigations and forensic toxicology results, at 
least some of the individuals were high-risk drug users and included people who had a 
history of injecting opioids such as heroin. Isotonitazene was identified along with one or 
more other psychoactive substances (controlled drugs and new psychoactive substances) in 
all the deaths, which suggests that polydrug use was common in these individuals. In 
particular, many of the cases involved the use of other CNS depressants along with 
isotonitazene (such as other opioids and/or benzodiazepines) (Krotulski et al., 2020). 
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4. Analysis and assessment  
N,N-Diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(isotonitazene) is a synthetic opioid analgesic. It is monitored by the EMCDDA as a new 
psychoactive substance in accordance with Regulation (EC) No 1920/2006 (as amended).  
Isotonitazene is a member of the benzimidazole family of opioids which includes 
etonitazene, a potent internationally controlled opioid analgesic. Currently available 
information suggests that isotonitazene may be a highly potent opioid analgesic. As such, 
the most serious acute risk from the use of isotonitazene is likely to be from respiratory 
depression, which can lead to apnoea, respiratory arrest, and death. Isotonitazene is the first 
of the benzimidazole opioids to be identified on the drug market in recent years, and users 
have no experience with this group of opioids (such as dose and effects) which may 
increase the risk of accidental life-threatening poisoning. This risk will be especially high if 
users are unaware that they are using isotonitazene, which may be the case when it is sold 
at street-level on the illicit opioid market. Importantly, the timely administration of the antidote 
naloxone has been shown to be effective in reversing respiratory depression caused by 
potent opioid analgesics such as isotonitazene. 
Isotonitazene has been available on the drug market in Europe since at least April 2019. The 
most recent identification of isotonitazene reported to the EMCDDA is a seizure made by 
police in January 2020. As of 28 March 2020, it has been identified in six Member States: 
Belgium, Estonia, Germany, Latvia, Sweden, and the United Kingdom. These detections 
relate to police seizures reported by Estonia, Germany, and Latvia; a customs seizure 
reported by Sweden; a collected sample reported by Belgium; and biological samples from a 
death case reported by the United Kingdom. While the detected quantities are relatively 
small, they should be seen within the context of the possible high potency of isotonitazene.  
It is important to note that the presence of isotonitazene on the drug market and in serious 
adverse events may be undetected in Europe since the substance is not routinely screened 
for in some laboratories. In addition, analytical sensitivity related to the analysis of biological 
samples from serious adverse events is a possible issue as the concentration of 
isotonitazene can be sub-nanogram to picogram. 
A total of two deaths involving isotonitazene have been reported by Germany and the United 
Kingdom. In addition, deaths have been reported in Canada (3 cases) and the United States 
(18 cases). At least some of the individuals from the United States were high-risk drug users 
and included people who had a history of injecting opioids such as heroin; polydrug use, 
especially use of two or more CNS depressants, was common. 
There is limited information on the manufacture, trafficking, distribution, and use of 
isotonitazene. It appears that at least some of the isotonitazene on the market in Europe has 
been produced by chemical companies based in China. It is sold online as a powder in small 
and wholesale amounts; it is also sold as ready to-use nasal sprays. Isotonitazene may also 
have also been sold on the illicit opioid market at street-level in at least two Member States. 
Isotonitazene may be deliberately sought after by some users; others, such as those that 
purchase it at street-level, may be unaware that they are using the substance which 
presents an inherent risk to the individuals. There is no information whether or not criminal 
groups are involved in the manufacture, trafficking, and distribution of isotonitazene within 
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Europe. The effect of the ongoing COVID-19 pandemic on the manufacture, trafficking, 
distribution, and use of isotonitazene is currently unknown. It is conceivable, that, should 
there be a reduced availability of established opioids in Europe, such as heroin, then 
criminal groups, as well as people who use opioids (especially high-risk opioid users), may 
use a range of replacement substances, including benzimidazole opioids such as 
isotonitazene. 
Isotonitazene has not been subject to assessment nor is currently under assessment by the 
United Nations system. Based on the available information, it appears that isotonitazene is 
not an active substance in a medicinal product for human use or in a veterinary medicinal 
product in Europe. However, the use of isotonitazene as an active substance in medicinal 
products prepared extemporaneously or in investigational medicinal products cannot be 
excluded in some Member States. 
There is currently no information that suggests isotonitazene is used for other legitimate 
purposes. 
Isotonitazene is subject to restrictive measures in six Member States: in Estonia, Latvia, 
Poland, and Sweden the substance is controlled under drug control legislation; in Lithuania it 
is controlled under medicines legislation; while in the United Kingdom it is controlled by new 
psychoactive substance legislation. In addition, isotonitazene is controlled under medicines 
legislation in Norway. It is unknown if isotonitazene is controlled in China, where at least 
some of the substance on the European market has been sourced from. 
The EMCDDA will continue to intensively monitor isotonitazene in order to ensure that new 
information is provided to the Member States, Europol, the Commission, and the EMA via 
the European Union Early Warning System in a timely manner in order to strengthen 
situational awareness as well as inform preparedness and response measures at both 
national and EU level in order to protect public health. 
Based on the analysis of the available information, the EMCDDA considers that there are 
indications that isotonitazene may pose health or social risks at Union level. We conclude 
that the potential health and social risks posed by the use, manufacture, distribution and the 
involvement of criminal groups, could be thoroughly assessed through a risk assessment 
procedure in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). 
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